Innovative retatrutide, a dual -action treatment targeting both GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Initial clinical trials have demonstrated substantial losses in body size and improvements in physiological markers for patients with excess weight . Experts believe this unique approach may